Sandesh Mahatme

2017

In 2017, Sandesh Mahatme earned a total compensation of $2.2M as Executive Vice President, Chief Financial Officer and Chief Business Officer at Sarepta Therapeutics, a 22% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$257,181
Option Awards$601,433
Salary$459,252
Stock Awards$867,827
Other$14,440
Total$2,200,133

Mahatme received $867.8K in stock awards, accounting for 39.44% of the total pay in 2017.

Mahatme also received $257.2K in non-equity incentive plan, $601.4K in option awards, $459.3K in salary and $14.4K in other compensation.

Rankings

In 2017, Sandesh Mahatme's compensation ranked 4,817th out of 14,046 executives tracked by ExecPay. In other words, Mahatme earned more than 65.7% of executives.

ClassificationRankingPercentile
All
4,817
out of 14,046
66th
Division
Manufacturing
1,737
out of 5,566
69th
Major group
Chemicals And Allied Products
504
out of 1,972
74th
Industry group
Drugs
385
out of 1,636
77th
Industry
Pharmaceutical Preparations
307
out of 1,260
76th
Source: SEC filing on April 26, 2018.

Mahatme's colleagues

We found six more compensation records of executives who worked with Sandesh Mahatme at Sarepta Therapeutics in 2017.

2017

Douglas Ingram

Sarepta Therapeutics

Chief Executive Officer

2017

Edward Kaye

Sarepta Therapeutics

Chief Executive Officer

2017

Guriqbal Basi

Sarepta Therapeutics

Chief Scientific Officer

2017

Alexander Cumbo

Sarepta Therapeutics

Senior Vice President, Chief Commercial Officer

2017

David Howton

Sarepta Therapeutics

General Counsel

2017

Catherine Stehman-Breen

Sarepta Therapeutics

Chief Medical Officer

News

You may also like